Concomitant Mutation Confers Worse Prognosis in -Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Apr 11

PMID 32272775

Citations 38

Authors

Matteo Canale

Elisabetta Petracci

Angelo Delmonte

Giuseppe Bronte

Elisa Chiadini

Vienna Ludovini

Alessandra Dubini

Maximilian Papi

Sara Baglivo

Nicoletta De Luigi

Alberto Verlicchi

Rita Chiari

Lorenza Landi

Giulio Metro

Marco Angelo Burgio

Lucio Crino

Paola Ulivi

Affiliations

Soon will be listed here.

Abstract

Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor ()-mutated patients usually benefit from TKIs treatment, but a significant portion show unresponsiveness due to primary resistance mechanisms. We investigated the role of mutations in predicting survival and response to -TKIs in EGFR-mutated NSCLC patients, to confirm, on an independent case series, our previous results.

Methods: An independent retrospective cohort study was conducted, on a case series of 136 -mutated NSCLC patients receiving first or second generation TKIs as a first line therapy, and a smaller fraction of patients who acquired the T790M resistance mutation and were treated with third generation TKIs in the second or further line of treatment. mutations were evaluated in relation to disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) of the patients.

Results: Forty-two patients (30.9%) showed a mutation. Considered together, mutations had no significant impact on time-to-event endpoints. Considering the different mutations separately, exon 8 mutations confirmed their negative effect on PFS (HR 3.16, 95% 1.59-6.28, = 0.001). In patients who developed the T790M resistance mutation, treated with third generation TKIs, the exon 8 mutations predicted worse PFS (even though not statistically significant), and OS (HR 4.86, 95% CI: 1.25-18.90, = 0.023).

Conclusions: exon 8 mutations confirmed their negative prognostic impact in patients treated with first and second generation TKIs and demonstrated a role in affecting clinical outcome in patients treated with third generation TKIs.

Citing Articles

EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer.

Goffinet S, Bontoux C, Heeke S, Pezzuto F, Ilie M, Long-Mira E Virchows Arch. 2024; .

PMID: 39741211 DOI: 10.1007/s00428-024-04010-4.

combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.

Terada N, Koba H, Nanjo S, Kimura H, Nishiyama A, Yoneda T Transl Lung Cancer Res. 2024; 13(11):3067-3082.

PMID: 39670006 PMC: 11632430. DOI: 10.21037/tlcr-24-471.

Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report.

Luo Y, Lin L, Shufeng C, Liu C, Li Z, Liu K Oncol Lett. 2024; 28(5):501.

PMID: 39233826 PMC: 11369848. DOI: 10.3892/ol.2024.14634.

Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.

Zhang Z, Xue J, Yang Y, Fang W, Huang Y, Zhao S MedComm (2020). 2024; 5(6):e586.

PMID: 38832214 PMC: 11144614. DOI: 10.1002/mco2.586.

TP53 gain-of-function mutations promote osimertinib resistance via TNF-α-NF-κB signaling in EGFR-mutated lung cancer.

Ibusuki R, Iwama E, Shimauchi A, Tsutsumi H, Yoneshima Y, Tanaka K NPJ Precis Oncol. 2024; 8(1):60.

PMID: 38431700 PMC: 10908812. DOI: 10.1038/s41698-024-00557-2.

References

Volckmar A, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J . Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. Int J Cancer. 2019; 145(3):649-661. DOI: 10.1002/ijc.32133. View

Jamal-Hanjani M, Wilson G, McGranahan N, Birkbak N, Watkins T, Veeriah S . Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(22):2109-2121. DOI: 10.1056/NEJMoa1616288. View

Yu H, Arcila M, Rekhtman N, Sima C, Zakowski M, Pao W . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013; 19(8):2240-7. PMC: 3630270. DOI: 10.1158/1078-0432.CCR-12-2246. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Brosh R, Rotter V . When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9(10):701-13. DOI: 10.1038/nrc2693. View

Poeta M, Manola J, Goldwasser M, Forastiere A, Benoit N, Califano J . TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007; 357(25):2552-61. PMC: 2263014. DOI: 10.1056/NEJMoa073770. View

Labbe C, Cabanero M, Korpanty G, Tomasini P, Doherty M, Mascaux C . Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer. 2017; 111:23-29. DOI: 10.1016/j.lungcan.2017.06.014. View

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M . Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019; 121(9):725-737. PMC: 6889286. DOI: 10.1038/s41416-019-0573-8. View

10.

Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S . TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis. Mol Clin Oncol. 2017; 5(6):705-713. PMC: 5228103. DOI: 10.3892/mco.2016.1057. View

11.

La Fleur L, Falk-Sorqvist E, Smeds P, Berglund A, Sundstrom M, Mattsson J . Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 2019; 130:50-58. DOI: 10.1016/j.lungcan.2019.01.003. View

12.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

13.

Chen M, Xu Y, Zhao J, Zhong W, Zhang L, Bi Y . Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. EBioMedicine. 2019; 42:304-310. PMC: 6491938. DOI: 10.1016/j.ebiom.2019.03.023. View

14.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

15.

Muller P, Vousden K . p53 mutations in cancer. Nat Cell Biol. 2012; 15(1):2-8. DOI: 10.1038/ncb2641. View

16.

Jin Y, Shi X, Zhao J, He Q, Chen M, Yan J . Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. Lung Cancer. 2018; 124:110-116. DOI: 10.1016/j.lungcan.2018.07.039. View

17.

Aggarwal C, Davis C, Mick R, Thompson J, Ahmed S, Jeffries S . Influence of Mutation on Survival in Patients With Advanced -Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 2018. PMC: 6372114. DOI: 10.1200/PO.18.00107. View

18.

Xu Y, Tong X, Yan J, Wu X, Shao Y, Fan Y . Short-Term Responders of Non-Small Cell Lung Cancer Patients to EGFR Tyrosine Kinase Inhibitors Display High Prevalence of TP53 Mutations and Primary Resistance Mechanisms. Transl Oncol. 2018; 11(6):1364-1369. PMC: 6132175. DOI: 10.1016/j.tranon.2018.08.010. View

19.

Liu Y, Xu F, Wang Y, Wu Q, Wang B, Yao Y . Mutations in exon 8 of are associated with shorter survival in patients with advanced lung cancer. Oncol Lett. 2019; 18(3):3159-3169. PMC: 6676404. DOI: 10.3892/ol.2019.10625. View

20.

Mok T, Wu Y, Ahn M, Garassino M, Kim H, Ramalingam S . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2016; 376(7):629-640. PMC: 6762027. DOI: 10.1056/NEJMoa1612674. View